Top Markets
Coin of the day
Handa Pharmaceuticals, Inc. Handa Pharmaceuticals, Inc.

Handa Pharmaceuticals, Inc.

6620
株式のランク #13397
Handa Pharmaceuticals, Inc. operates as a specialized drug company,... Handa Pharmaceuticals, Inc. operates as a specialized drug company, concentrating its efforts on creating and advancing new medications for diverse health issues across both the United States and China. The firm currently offers Quetiapine XR, a treatment for Schizophrenia, as well as Dexlansoprazole DR capsules. Beyond its existing portfolio, Handa is actively cultivating a robust pipeline of therapies. This includes their cutting-edge ONCORE drug delivery platform, engineered to boost patient adherence and improve the safety of tyrosine kinase inhibitor oncology drugs. Other significant projects encompass a 505(b)(2)NDA therapeutic agent, Tascenso ODT for managing multiple sclerosis, and the oncology candidates HND-033 and HND-027. Furthermore, the company's development initiatives feature HND-004, designed for diabetic patients; HND-032, intended to aid in smoking cessation; and HND-026, a gastrointestinal medication. Founded in 2014, Handa Pharmaceuticals, Inc. has its main corporate headquarters situated in Tainan City, Taiwan.
株価
$2.95
時価総額
$491.95M
変化(1日)
9.94%
変化(1年)
8.06%
TW
取引 Handa Pharmaceuticals, Inc. (6620)

カテゴリー

Handa Pharmaceuticals, Inc.(6620)の利益
2026 時点の利益 TTM: 0
Handa Pharmaceuticals, Inc. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Handa Pharmaceuticals, Inc. の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。